Evidence map›Paper›PMID 40867624›Full record

ArticleBiomolecules2025

Discovery of Novel 2-Substituted Aniline Pyrimidine Based Derivatives as Potent Mer/c-Met Dual Inhibitors with Improvement Bioavailability.

Jixia Yang, Daowei Huang, Ruojin Wang, Pengxin Fan, Rourou Li, Donglai Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jixia YangSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Daowei HuangSchool of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China.
Ruojin WangSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Pengxin FanSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Rourou LiSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Donglai MaSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.ORCID 0000-0002-5398-1725

Funding

College Students' Innovation and Entrepreneurship Training Program 202314432007Doctoral Research Fund Project BSZ2022004National Natural Science Foundation of China 82003601Science Research Project of Hebei Education Department BJK2024144Special Project for Basic Research Business Expenses of Provincial Universities JCYJ2023004
6 · The paper itself

Abstract

This study reports the rational design and systematic evaluation of a novel series of 2-substituted aniline pyrimidine derivatives as dual Mer/c-Met inhibitors. Among the synthesized compounds, 17c demonstrated potent dual kinase inhibition, with IC

Indexed as

Aniline CompoundsProtein Kinase InhibitorsPyrimidinesReceptor Protein-Tyrosine KinasesAnimalsApoptosisBiological AvailabilityCell ProliferationCHO CellsCricetinaeCricetulusHumansLigandsMicrosomes, LiverMolecular Docking SimulationMolecular StructureanilineAniline CompoundsLigandsProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyrimidinesReceptor Protein-Tyrosine Kinases2-substituted aniline pyrimidineanti-cancerc-Met kinaseMer/c-Met dual inhibitorMer kinase

Identifiers

PMID40867624
PMCPMC12385147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.